Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide in gastrointestinal disorders.

A Bousvaros1, B Mueller

  • 1Division of Gastroenterology, Boston Children's Hospital/Harvard Medical School, Massachusetts 02115, USA. bousvaros@a1.tch.harvard.edu

Drugs
|June 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of predelivery fetal echocardiography, cardiac magnetic resonance imaging and acute maternal hyperoxygenation in predicting urgency of neonatal balloon atrial septostomy in fetal dextro-transposition of the great arteries.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2026
Same author

Muscle matters: Prognostic implications of malnutrition and muscle health parameters in patients with cancer. A secondary analysis of a randomised trial.

Clinical nutrition (Edinburgh, Scotland)·2024
Same author

Gingival Conditioning with Provisional Composite Veneer Prior to Final Dental Restoration: Three-year Follow-up.

Operative dentistry·2023
Same author

Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Cytokines and Cortisol - predictors of treatment response to corticosteroids in community-acquired pneumonia?

Journal of internal medicine·2019
Same author

How to: implement procalcitonin testing in my practice.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Thalidomide, once a sedative, is now used for immune-related gastrointestinal conditions. Strict birth control is essential due to severe birth defect risks, with other side effects including sedation and neuropathy.

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Thalidomide, initially a sedative, was withdrawn due to severe teratogenicity.
  • It has demonstrated efficacy in gastrointestinal disorders involving immune dysregulation.
  • Mechanisms of immunosuppression, such as TNF-alpha inhibition and anti-angiogenesis, are under investigation.

Purpose of the Study:

  • To review the therapeutic applications of thalidomide in immune-mediated gastrointestinal diseases.
  • To summarize efficacy and safety data for thalidomide in specific conditions.
  • To highlight critical safety considerations, particularly teratogenicity.

Main Methods:

  • Literature review of studies on thalidomide in gastrointestinal and immune-related diseases.
  • Analysis of reported efficacy in conditions like chronic graft versus host disease, HIV-associated aphthous ulceration, Behçet's disease, and Crohn's disease.

Related Experiment Videos

  • Compilation of data on adverse effects and necessary precautions.

    • Main Results:

    • Thalidomide shows variable efficacy: 20% response in refractory chronic graft versus host disease, 50% ulcer eradication in HIV-associated aphthous ulceration, and reduction in mucocutaneous ulcers in Behçet's disease.
    • It may decrease severity in Crohn's disease and promote fistula closure.
    • Common adverse effects include sedation (nearly all patients), neuropathy (~20%), and rashes.

    Conclusions:

    • Thalidomide is a valuable therapeutic option for specific immune-mediated gastrointestinal conditions.
    • Strict adherence to safety protocols, including robust contraception, is mandatory due to teratogenic potential.
    • Use should be confined to clinical protocols with oversight due to significant toxicity.